Anavex Life Sciences to Announce Fiscal 2020 Second Quarter Financial Results on Thursday, May 7th, 2020

Rhea-AI Summary

Anavex Life Sciences Corp. (Nasdaq: AVXL) has announced it will release its financial results for the fiscal quarter ending March 31, 2020, on May 7, 2020. This will be followed by a conference call at 4:30 PM ET to discuss the results and updates on clinical programs. Anavex is focused on developing therapeutics for neurodegenerative diseases, including Alzheimer's and Parkinson's. Their leading candidate, ANAVEX®2-73 (blarcamesine), has shown promise in clinical trials and is aimed at restoring cellular homeostasis.

Positive

• ANAVEX®2-73 (blarcamesine) completed a successful Phase 2a clinical trial for Alzheimer's disease.
• The drug candidate demonstrated potential to halt/reverse Alzheimer's disease progression.
• ANAVEX®3-71 showed beneficial effects against Alzheimer's disease in preclinical trials.

Negative

• None.

NEW YORK, May 05, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that it will issue financial results for its fiscal quarter ended March 31, 2020 on Thursday, May 7^th, 2020.

Management will host a conference call on Thursday, May 7^th, 2020 at 4:30pm Eastern Time to review financial results and provide an update on its clinical programs and corporate highlights. Following management’s formal remarks, there will be a question and answer session with equity analysts.

Conference Call / Webcast Information:

The live webcast of the conference call can be accessed online at http://www.wsw.com/webcast/cc/avxl13.
To join the conference call, live via telephone, interested parties within the U.S. should dial, toll-free, 1 (866) 939-3921 and international callers should dial 1 (678) 302-3550. Please use confirmation number 49673201, followed by the pound sign (#).

A replay of the conference call will also be available on www.anavex.com.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidate, ANAVEX^®2-73 (blarcamesine), recently completed a successful Phase 2a clinical trial for Alzheimer’s disease. ANAVEX^®2-73 (blarcamesine) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. ANAVEX^®2-73 (blarcamesine) also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson’s Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX^®2-73 (blarcamesine) for the treatment of Parkinson’s disease. ANAVEX^®3-71, which targets sigma-1 and muscarinic receptors, is a promising preclinical drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies. In preclinical trials, ANAVEX^®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the company on Twitter, Facebook and LinkedIn.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For Further Information:

Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email:  info@anavex.com

Investors & Media:
Email: ir@anavex.com

FAQ

When will Anavex report its financial results for Q1 2020?

Anavex will report its financial results for the fiscal quarter ending March 31, 2020, on May 7, 2020.

What is the ticker symbol of Anavex Life Sciences?

The ticker symbol of Anavex Life Sciences is AVXL.

What is ANAVEX®2-73 and its significance?

ANAVEX®2-73 (blarcamesine) is Anavex's lead drug candidate that has shown promise in treating Alzheimer's disease.

What time is the Anavex conference call on May 7, 2020?

The conference call will take place at 4:30 PM ET.

How can I access the Anavex conference call?

The conference call can be accessed via telephone or through a live webcast available on Anavex's website.